Alexandra Desnoyers

Wilson BE, Desnoyers A, Nadler MB, Amir E, Booth CM

Differential treatment effect between younger and older adults for new cancer therapies in solid tumors supporting US Food and Drug Administration approval between 2010 and 2021

Cancer, 129 (20), 2023.

Résumé | Liens:

Leblanc D, Cantin G, Desnoyers A, Dufresne J, Masucci GL, Panet-Raymond V, Poirier É, Soldera S, Gingras I

Management of Oligometastatic Breast Cancer: An Expert Committee's Opinion

Curr Oncol, 30 (2), 2023.

Résumé | Liens:

Nadler MB, Corrado AM, Wilson BE, Desnoyers A, Amir E, Ivers N, Desveaux L

Perceived guideline clarity impacts guideline-concordant care for breast cancer screening in women age 40-49

BMC Womens Health, 23 (1), 2023.

Résumé | Liens:

Nadler MB, Corrado AM, Desveaux L, Neil-Sztramko SE, Wilson BE, Desnoyers A, Amir E, Ivers N

Determinants of guideline-concordant breast cancer screening by family physicians for women aged 40-49 years: a qualitative analysis

CMAJ Open, 10 (4), 2022.

Résumé | Liens:

Desnoyers A, Wilson BE, Nadler MB, Amir E

Fragility index of trials supporting approval of anti-cancer drugs in common solid tumours

Cancer Treat Rev, 94 , 2021.

Résumé | Liens:

Jolivet C, Nassabein R, Soulières D, Weng X, Amireault C, Ayoub JP, Beauregard P, Blais N, Carrier C, Cloutier AS, Desnoyers A, Lemay AS, Lemay F, Loungnarath R, Jolivet J, Letendre F, Tehfé M, Vadnais C, Viens D, Aubin F

Implementing DPYD*2A Genotyping in Clinical Practice: The Quebec, Canada, Experience

Oncologist, 26 (4), 2021.

Résumé | Liens:

Al-Showbaki L, Nadler MB, Desnoyers A, Almugbel FA, Cescon DW, Amir E

Network Meta-analysis Comparing Efficacy, Safety and Tolerability of Anti-PD-1/PD-L1 Antibodies in Solid Cancers

J Cancer, 12 (14), 2021.

Résumé | Liens:

Desnoyers A, Amir E, Tannock IF

Adjuvant Zoledronate Therapy for Women With Breast Cancer-Effective Treatment or Fool's Gold?

JAMA Oncol, 7 (8), 2021.

| Liens:

Wilson BE, Desnoyers A, Nadler MB, Tibau A, Amir E

Fragility of randomized trials supporting cancer drug approvals stratified by approval pathway and review designations

Cancer Med, 10 (16), 2021.

Résumé | Liens:

Wilson BE, Nadler MB, Desnoyers A, Amir E

Quantifying Withdrawal of Consent, Loss to Follow-Up, Early Drug Discontinuation, and Censoring in Oncology Trials

J Natl Compr Canc Netw, 19 (12), 2021.

Résumé | Liens: